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BaculovirusThe function of the hepatitis B virus (HBV) wild-type (WT) polymerase (pol) expressed alone or in the
context of the intact genome when interacting with HBV rtM204I in HepG2 cells was compared. We show
that WT pol expression from a packaging-defective RNA can complement defective rtM204I pol activity
resulting in increased levels of HBV replicative intermediates (RI). Analysis of the genetically marked
genomes showed that this restoration resulted from trans-complementation, rather than recombination. In
contrast, we demonstrate that enhanced levels of total HBV RI observed when cells were cotransduced with
both WT and rtM204I baculoviruses were predominantly WT RI. In this case, WT pol was produced from a
full-length pregenomic RNA (pgRNA). We conclude that the WT pol has the capacity to trans-complement
the replication defect of rtM204I; however, when expressed from an authentic pgRNA, as in a mixed
infection, pol may not trans-complement efﬁciently.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hepatitis B virus (HBV) causes acute and chronic infections of the
liver and is responsible for 1.2 million deaths annually. Approximately
0.5% of acute infections terminate in fatal, fulminant hepatitis. The
WHO currently estimates that 350 million people are chronically
infected with HBV.
The approved agents for the treatment of HBV chronically infected
individuals include α-interferon and ﬁve nucleoside/tide analogues:
lamivudine (3TC, Epivir-HBV), adefovir dipivoxil (Hepsera), entecavir
(Baraclude), telbivudine (Tyzeka), and tenofovir (Viread). Lamivudine
treatment has been very useful in reducing HBV DNA levels in patient
sera and shows very limited side effects (Dienstag et al., 1999; Jarvis
and Faulds, 1999; Santantonio et al., 2000); however, the emergence
of drug-resistant mutants occurs at high frequency, (Allen et al., 1998;
Bartholomew et al., 1997; de Man et al., 1999; Honkoop et al., 1997;
Liaw et al., 1999; Peters et al., 1999) with the incidence of resistance
after 1 year of treatment ranging from 17% (Chang et al., 2004) to 32%
(Lai et al., 2003; Mauss and Wedemeyer, 2008). The most commony and Immunology, Milton S.
cine, 500 University Drive, P.O.
.
ll rights reserved.mutations occur within the catalytic YMDD motif of the HBV pol,
resulting in the replacement of methionine with either valine or
isoleucine at amino acid 204 (Allen et al., 1998; Ono-Nita et al., 1999).
In vitro, the rtM204I lamivudine-resistant mutant replicates to
signiﬁcantly lower levels compared to wild-type (WT) HBV (Fu and
Cheng, 1998; Gaillard et al., 2002; Melegari, Scaglioni, and Wands,
1998; Ono-Nita et al., 1999). We recently reported that the rtM204I
mutant has a defect in replication, resulting in diminished levels of
HBV intracellular replicative intermediates (RI) and extracellular (EC)
DNA compared to WT HBV after day 5 post-transduction (p.t.) with
HBV recombinant baculovirus (Heipertz et al., 2007). In contrast, in
vivo, as drug-resistant mutants emerge, there is an increase in viral
load and serum alanine aminotransferase levels as well as a
deterioration of liver histology. Indeed, lamivudine-resistant mutants
have also been associated with death in several case studies (Kagawa
et al., 2004; Kim et al., 2001; Suzuki et al., 2007; Wang et al., 2002).
Interestingly, it appears that the rtM204I and rtM204V mutants
can preexist in naïve patients (Pallier et al., 2006; Zhang et al., 2003).
This is most likely due to the fact that HBV pol lacks proofreading
function, leading to a relatively high frequency of mutations/site/year
(Girones and Miller, 1989). Therefore, WT and rtM204I HBV viruses
can potentially be present in the same hepatocyte, which could lead to
an interaction between WT virus and lamivudine-resistant mutants.
The interplay of HBV viral components, speciﬁcally, the rescue of a
pol-deﬁcient mutant virus by the expression of a WT pol in trans, has
Fig. 1. Generation and screen of HBV pol-expressing recombinant baculoviruses. (A)
Schematic representation of CMV promoter-driven, C-terminally FLAG-tagged HBV pol-
expressing recombinant baculoviruses PCF and PCFE. PCF and PCFE differ only in the
presence of the 3′ epsilon sequence contained within PCFE. (B) Southern blot analysis of
HBV RI DNA extracted from HepG2 cells transfected with 3 μg of the replication-
deﬁcient HBV plasmid, pdMfe, 4 days p.t. with pol-expressing recombinant baculo-
viruses PCF or PCFE at various MOIs. HBV RI DNA extracted from HBV recombinant
baculovirus-transduced HepG2 cells 4 days p.t. was included as a positive control. MOI,
multiplicity of infection (pfu/cell); RC, relaxed-circular; DS, double-stranded linear; SS,
single-stranded; +, presence of pdMfe; −, absence of pdMfe.
Fig. 2. trans-Complementation of a replication-deﬁcient HBV expression plasmid by
HBV pol-expressing recombinant baculoviruses. Southern blot analysis of restriction
enzyme digested HBV RI DNA. HepG2 cells were transduced with HBV pol-expressing
recombinant baculoviruses, PCF or PCFE, at a MOI of 200 pfu/cell 24 h post-transfection
with 3 μg of the replication-deﬁcient HBV expression plasmid, pdMfe. HepG2 cells were
transduced withWT HBV recombinant baculovirus at a MOI of 100 pfu/cell as a positive
control. Four days p.t., HBV RI DNA was extracted and equal concentrations were left
undigested or digested with EcoR I or Mfe I at 37 °C for 1 h and visualized by Southern
blot analysis. U, Undigested; E, EcoR I digested; M, Mfe I digested, MOI, multiplicity of
infection (pfu/cell); RC, relaxed-circular; DS, double-stranded linear; SS, single-
stranded; +, presence of pdMfe; −, absence of pdMfe.
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demonstrated when the mutant virus encodes a pol containing a
missense codon, rendering the viral pol nonfunctional for RNA
encapsidation (Blum et al., 1991), and when the mutant virus encodes
a nonsense mutation, preventing the expression of the pol (Bartens-
chlager, Junker-Niepmann, and Schaller, 1990; Chiang et al., 1990;
Junker-Niepmann, Bartenschlager, and Schaller, 1990; Okamoto et al.,
1993; Radziwill, Tucker, and Schaller, 1990; Yaginuma et al., 1987).
Other mutant viral proteins such as the core protein (HBcAg) and the
surface protein (HBsAg) can also be rescued through trans-comple-
mentation (Chiang et al., 1990; Junker-Niepmann, Bartenschlager, and
Schaller, 1990; Okamoto et al., 1993; Radziwill, Tucker, and Schaller,
1990; Yaginuma et al., 1987).
The goal of the current study was to compare the function of the
HBVWT pol expressed alone or in the context of the intact HBV genome
in HepG2 cells transduced with the lamivudine-resistant rtM204I. To
achieve this goal, we took advantage of the recombinant baculovirus-
mediated HBV transduction of HepG2 cells, which allows highly
efﬁcient transduction of WT and mutant HBV genomes or individual
genes and detailed analyses of all post-entry steps of HBV replication.
Results
Generation of recombinant baculovirus that is expressing functional HBV
pol
Two WT HBV pol recombinant baculoviruses designated PCF and
PCFE were generated (Fig. 1A). PCF and PCFE are C-terminally FLAG-
tagged, CMV promoter-driven, HBV pol-expressing recombinant
baculoviruses lacking the 5′ epsilon and differing from each other
only in the presence of the 3′ epsilon contained within PCFE. The
ability of PCF and PCFE to express a functional HBV pol was tested in
the context of the replication-deﬁcient HBV expression plasmid,
pdMfe, which lacks a functional pol. Twenty-four hours following
transfection with 3 μg of pdMfe, HepG2 cells were transduced with
pol-expressing baculoviruses, PCF or PCFE, at various MOIs. HBV RI
were harvested from infected cells 4 days p.t. and visualized by
Southern blot analysis. As shown in Fig. 1B, both PCF and PCFE were
able to rescue the replication-deﬁcient pdMfe in a MOI-dependent
manner up to a MOI of 100 pfu/cell. The efﬁcacy of PCF and PCFE
appear equal, suggesting that the presence or absence of an epsilon
sequence does not inﬂuence the ability of the pol to rescue thedeﬁcient pdMfe. It is important to note that PCF and PCFE (Fig. 1B,
lanes 6 and 12, respectively), as well as pdMfe (Fig. 1B, lane 13) are
incapable of producing a detectable signal when individually
expressed in HepG2 cells, indicating that these constructs are
replication-deﬁcient. Due to the unique arrangement of the HBV
genome, PCF and PCFE could have the potential to produce HBsAg;
however, neither PCFE nor PCF produced detectable levels of HBsAg
(data not shown).
pdMfe is a HBV expression plasmid that is replication-deﬁcient due
to a frameshift mutationwithin the pol open reading frame caused by
a four-nucleotide insertion, which also results in the loss of the single
Mfe I restriction enzyme site present in the HBV genome. To
determine whether the rescue of the replication-deﬁcient pdMfe
was indeed due to trans-complementation by the recombinant
baculoviruses PCF and PCFE and not due to recombination of the
introduced HBV DNAs, restriction enzyme digestions of the HBV RI
were conducted (Fig. 2). Equal concentrations of RI DNA from either
WT HBV recombinant baculovirus-transduced HepG2 cells and PCF or
PCFE recombinant baculovirus-transduced, pdMfe transfected HepG2
cells were digested with EcoR I and Mfe I or undigested and visualized
by Southern blot analysis. As shown in Fig. 2, RI DNA from WT HBV
baculovirus-transduced HepG2 cells was digested with bothMfe I and
EcoR I, resulting in the conversion of the relaxed-circular (RC) RI
species to the double-stranded linear (DS) form and a downward shift
in the digested DS form due to the single presence of each restriction
enzyme site within the WT HBV genome. However, RI DNA from PCF
and PCFE baculovirus-transduced, pdMfe transfected HepG2 cells was
only digested by EcoR I, indicating that the single Mfe I site contained
within the HBV genome was not restored. Taken together, the data
indicate that both PCF and PCFE express a functional HBV pol that is
capable of complementing the replication-deﬁcient pdMfe in trans. In
addition, the epsilon sequence does not need to be present in the
construct to produce functional HBV pol. The remaining experiments
were carried out with only the 3′ epsilon-containing construct, PCFE.
Effect of the WT pol construct PCFE on the replication of the lamivudine-
resistant mutant rtM204I
The goal of these experiments was to examine the effect of the WT
pol construct PCFE on the replication of the lamivudine-resistant
mutant rtM204I. Examining the effect of theWT pol construct PCFE on
the replication of the WT HBV was included as a control. HepG2 cells
were seeded in 60-mm dishes, grown for 16 to 24 h, and then
transduced with 100 pfu/cell of WT or rtM204I HBV recombinant
baculovirus. Cells were fed every-other day and maintained until day
59R.A. Heipertz Jr. et al. / Virology 388 (2009) 57–6710 p.t. At day 10 p.t., two 60-mmdishes that had been transducedwith
either WT or rtM204I recombinant baculovirus were harvested for
HBV EC DNA as well as intracellular HBV RI and nuclear covalently
closed circular (CCC) DNA. A digital image of HBV RI DNA is shown inFig. 3. Effect of the WT pol construct, PCFE, on the replication of WT HBV and the lamivudin
eitherWTor rtM204I HBV recombinant baculovirus. At day 10 p.t., cells were harvested for HB
10 CCC DNA (E). Cells not harvested were subcultured 1:4 at day 10 p.t., grown for 16 to 24 h
days p.t. (now post-mock- or PCFE-transduced). Digital images of HBV RI DNA are shown (B)
shown (F) along with quantiﬁcation of rtM204I (G) andWT (H) HBV. PCFE, WT pol construct
HBV+PCFE 100 pfu/cell; gray bars, rtM204I HBV alone; striped bars, rtM204I HBV+PCFEFig. 3A and HBV CCC DNA is shown in Fig. 3E. Quantiﬁcation of HBV RI
DNA andHBV CCC DNA are shown in Figs. 3A and E, respectively. These
data agree with those previously reported. Speciﬁcally, at day 10 p.t.,
there is a marked decrease in HBV RI DNA when comparing rtM204Ie-resistant mutant rtM204I. HepG2 cells were transduced on day 0 with 100 pfu/cell of
V RI and CCC DNA. Digital images and quantiﬁcation are shown for day 10 RI (A) and day
, and mock- or PCFE-transduced. HBV RI and CCC DNA were extracted on the indicated
along with quantiﬁcation of rtM204I (C) andWT (D) HBV. Digital images of CCC DNA are
; P.T., post-transduction; P.S., post subculture. Black bars, WT HBV alone; white bars, WT
100 pfu/cell.
Fig. 4. Partial restoration of rtM204I replication in the presence of PCFE is accomplished
through trans-complementation. HepG2 cells were transduced at day 0 with 100 pfu/
cell of either WT or rtM204I HBV recombinant baculovirus and maintained until day 10
p.t. when the transduced cells were subcultured 1:4. The cells were either mock-
transduced or transduced with PCFE (MOI=100) or WT HBV (MOI=100). Cells were
harvested at day 5 p.t., day 6 post subculture. HBV RI DNA was digested under the
following conditions: Uncut [U], EcoR I cut [E], Cla I cut [C]. RtM204I is represented in
(A) and WT HBV is represented in (B). The far right panel of (A) is a darker exposure of
rtM204I Mock to illustrate the digestion pattern of rtM204I HBV RI DNA. PCFE, WT pol
construct; P.T., post-transduction; P.S., post subculture; U, Uncut; E, EcoR I cut; C, Cla I
cut; RC, relaxed-circular; DS, double-stranded linear; SS, single-stranded.
60 R.A. Heipertz Jr. et al. / Virology 388 (2009) 57–67and WT viruses and no differences in the levels of CCC DNA (Heipertz
et al., 2007). The data obtained for HBV EC DNA paralleled that for HBV
RI, also in agreement with data previously published [data not shown]
(Heipertz et al., 2007). In more recent studies, we have also shown
that at day 10 p.t. the levels of HBV nucleocapsids are the same for
both WT and rtM204I [Heipertz and Isom, unpublished data] (Fig. 5).
Therefore, at day 10 p.t., rtM204I replication proceeds at WT levels
through the encapsidation step but very low levels of HBV RI
compared to WT are produced, suggesting that rtM204I pol function
is defective in some manner.
At day 10 p.t., 60-mm dishes that were transduced with either
rtM204I or WT (as a control) recombinant baculovirus and not
harvested for day 10 analysis, were split 1:4 into new 60-mm dishes.
The HBV baculovirus subculture system, which has been previously
described and characterized(Starkey, Chiari, and Isom, 2009), pro-
vides HepG2 cells in which HBV replication is ongoing and are at the
appropriate cell density for quantitative transduction with a recombi-
nant baculovirus. Subcultured cells were transduced at 100 pfu/cell
with the WT pol construct, PCFE, or were mock-transduced. On the
indicated days p.t., cells were harvested for HBV RI (Figs. 3B–D) and
CCC DNA (Figs. 3F–H) and media was harvested for HBV EC DNA (data
not shown). It is important to note that days p.t. now refers to post-
transduction with PCFE- or mock-transduction of subcultured, WT or
rtM204I-expressing HepG2 cells. The digital images of HBV RI DNA are
shown in Fig. 3B. Quantiﬁcation of rtM204I HBV RI DNA is shown in
Fig. 3C. The addition of PCFE caused an increase in the amount of RI
DNA when comparing PCFE-transduced (striped bars) to mock-
transduced (gray bars) cells (Fig. 3C) through the time course studied.
A similar increasewas observed for rtM204I EC DNA (data not shown).
The maximum level of HBV RI and EC DNAs when comparing rtM204I
+100 pfu/cell PCFE to WT HBV alone was approximately 50% of the
WT level at day 4 p.t. As expected, there was no signiﬁcant difference
in the levels of WT HBV RI DNA whether the cells were mock-
transduced (black bars) or PCFE-transduced (white bars) at an MOI of
100 pfu/cell (Fig. 3D).
The levels of HBV CCC DNA were examined using the same
experimental approach. Intact nuclei were separated from the
cytoplasm, which was used for HBV RI isolation, from a single 60-
mm dish and used for preparation of CCC DNA, thereby enabling a
direct comparison of RI and CCC DNA from the same culture. The level
of HBV CCC DNAwas compared after the 1:4 split at the indicated time
points post PCFE- (MOI of 100 pfu/cell) or mock-transduction. The
digital image of HBV CCC DNA is shown in Fig. 3F. Quantiﬁcation of
rtM204I HBV CCC DNA (Fig. 3G) shows no difference between mock-
transduced (gray bars) and PCFE-transduced (striped bars) cells. This
ﬁnding for rtM204I CCC DNA is in contrast to what was observed for
rtM204I RI which was enhanced by transduction with 100 pfu/cell of
PCFE. However, this result for CCC DNA was expected because the
levels of rtM204I and WT CCC DNA remain comparable throughout
the time course (Heipertz et al., 2007). Quantiﬁcation of WT HBV CCC
DNA (Fig. 3H) also indicates that there is no difference betweenmock-
transduced (black bars) and PCFE-transduced (white bars) cells as
expected.
Increase in rtM204I replication following the addition of PCFE is
accomplished by trans-complementation
Restriction enzyme digestion analysis was utilized to determine
whether the increase in rtM204I replication observed after the
addition of the WT pol construct, PCFE, was due to recombination or
trans-complementation. The incorporation of the rtM204I mutation
in the WT HBV genome adds a unique Cla I restriction enzyme site,
allowing for the differential digestion of the rtM204I and WT HBV
genomes. HepG2 cells transduced with rtM204I or WT (control) HBV
baculovirus were maintained until day 10 p.t. At that time point, cells
were split 1:4 into 60-mm dishes and grown overnight. Twenty-fourhours post subculture, the cells were either mock-treated or
transduced with PCFE (MOI of 100) or WT HBV recombinant
baculovirus (MOI of 100). Cells were harvested for all conditions at
day 6 post subculture (Figs. 4A, B). RI was digested under the
following conditions: Uncut [U], cut with EcoR I [E] as a single-cut
control, or cut with Cla I [C]. When rtM204I expressing HepG2 cells
were mock-transduced or transduced with PCFE, there was a clear
shift downward of the RI DNA digested with Cla I (Fig. 4A). This shift is
due to the conversion of HBV RC DNA to the DS DNA form. A longer
exposure of HepG2 cells expressing rtM204I and subsequently mock
transduced is shown in the panel to the right so as to more clearly
indicate the downward shift that occurs following Cla I digestion of
rtM204I RI. When rtM204I expressing HepG2 cells were transduced
with WT HBV baculovirus, no shift occurred as expected (Fig. 4A).
When WT HBV expressing HepG2 cells were mock-, PCFE-, or WT
HBV-treated, RI was only digested by EcoR I and not Cla I (Fig. 4B),
regardless of the condition as expected. The data in Fig. 4A clearly
indicate that the RI generatedwhen rtM204I replicationwas increased
by transduction with PCFE is rtM204I DNA and not WT DNA and as
such, the increase in HBV replication observed is accomplished
through trans-complementation of rtM204I HBV by WT HBV pol.
trans-Complementation of rtM204I is not due to an increase in the total
amount of pgRNA packaging
Given the cis-preference of RNA packaging by the pol, the ability of
WT pol to trans-complement a mutant pol such as rtM204I that is
fully functional in RNA packaging was quite unexpected. One
possibility is that trans-complementation is due to an increase in
the total amount of pregenomic RNA (pgRNA) packagingwhen PCFE is
Fig. 5. trans-Complementation of rtM204I is not due to an increase in the total amount
of pgRNA packaging. HepG2 cells were transduced with 100 pfu/cell of rtM204I HBV
recombinant baculovirus. At day 10 p.t., cells were harvested for HBV intracellular
nucleocapsids (B) and HBV RI DNA (C). A digital image for day 10 is shown for WT and
rtM204I nucleocapsids (B; far left image) and for WT and rtM204I RI DNA (C; far left
image). Cells not harvested were subcultured 1:4 at day 10 p.t., grown for 16 to 24 h, and
mock- or PCFE-transduced. HBV intracellular nucleocapsids and HBV RI DNA were
extracted on the indicated days p.t. (now post-mock- or PCFE-transduced), analyzed by
Southern blot using a PhosphorImager, and quantitated using ImageQuant software.
Digital image and quantitation of RNA nucleocapsid (B) and HBV RI DNA (C) are shown.
Panel (A) demonstrates a dilution of day 10 p.t. WT and rtM204I nucleocapsid samples
to illustrate that a Southern blot of RNA contained within HBV nucleocapsids can be
accurately measured at various concentrations of sample. PCFE, WT pol construct; +,
transduced with PCFE; P.T., post-transduction; P.S., post subculture. Gray bars, rtM204I
HBV alone; striped bars, rtM204I HBV+PCFE 100 pfu/cell.
Fig. 6. Increase in the total amount of HBV RI DNA during a WT (MOI=25 pfu/cell)+
rtM204I (MOI=100 pfu/cell) cotransduction is not due to a boost in rtM204I genome
replication. HepG2 cells were transduced on day 0 under the following conditions: WT
HBVMOI=25 pfu/cell, rtM204I HBVMOI=100 pfu/cell, WT HBVMOI=25 pfu/cell+
rtM204I HBV MOI=100 pfu/cell. Cells were harvested for HBV RI DNA at day 3 and day
5 (data now shown) as well as day 20 and day 25 p.t. At the indicated time points p.t.,
HBV RI DNA was extracted and enzymatically digested under the following conditions:
Uncut [U], EcoR I cut [E], Cla I cut [C]. Co, cotransduction; P.T., post-transduction; U,
Uncut; E, EcoR I cut; C, Cla I cut; RC, relaxed-circular. Southern blot hybridization was
carried out using a [α-32P] dCTP-radiolabeled probe generated from a full-length,
double-stranded HBV genome.
Table 1
Levels of HBV RC and DS DNA in RI after cotransduction of HepG2 cells with WT and
M204I baculovirusesa.
Uncut Cla I cut
HBV DNA (pg) Fold increase
(WT+M204I)
HBV DNA (pg) Fold increase
(WT+M204I)
WT WT+M204I WT WT WT+M204I WT
Day 20b
RC 27.3 89.6 3.28 36.9 106.7 2.89
DS 43.1 57.6 1.34 41.6 61.9 1.49
RC+DS 70.4 147.2 2.09 78.5 168.6 2.15
Day 25b
RC 47.6 114.5 2.41 65.2 135.3 2.08
DS 66.9 92.0 1.38 76.7 101.2 1.32
RC+DS 114.5 206.5 1.80 141.9 236.5 1.67
a HepG2 cells were transduced under the following three conditions: WT MOI of
25 pfu/cell, rtM204I MOI of 100 pfu/cell, and WT MOI of 25 pfu/cell+rtM204I MOI of
100 pfu/cell.
b Data for rtM204I alone are not included because the DNA levels were below the
limits of detection.
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single molecule of pol is contained within nucleocapsids and that the
increase in HBV RI DNA observed during PCFE trans-complementation
is due to PCFE recognizing free (excess) rtM204I pgRNA that is not
being encapsidated by the rtM204I pol. To determine the level of
encapsidation during PCFE trans-complementation, HepG2 cells were
seeded in 60-mm dishes, grown for 16 to 24 h, and then transduced
with 100 pfu/cell of rtM204I or WT recombinant baculovirus.
Transduced cells were fed every-other day until day 10 p.t. when
they were harvested for intracellular nucleocapsids and HBV RI DNA.
Day 10 WT and rtM204I nucleocapsids were serially diluted toevaluate the ability of the nucleocapsid assay to distinguish two-fold
differences. The data clearly show that the output signal varies with
the input (Fig. 5A). Parallel cultures of rtM204I-transduced HepG2
cells, not harvested on day 10, were subcultured 1:4 and the following
day mock-transduced or transduced with the WT pol construct PCFE.
On the indicated days post-mock or PCFE transduction, HepG2 cells
were harvested for intracellular nucleocapsids (Fig. 5B) or HBV RI DNA
(Fig. 5C). WT levels of intracellular nucleocapsids and HBV RI DNA at
day 10 p.t. are also provided for comparison. No increase in the level of
pgRNA encapsidation was observed when cells were transduced with
PCFE (Fig. 5B). The addition of PCFE did cause an increase in rtM204I
RI levels as observed previously. By day 14 p.t., RI levels from cells
transduced with PCFE were approximately 9-fold higher than for
rtM204I alone. These data indicate that trans-complementation of
rtM204I by PCFE was not caused by an increase in total pgRNA
packaging.
Increase in total HBV RI DNA during a WT/rtM204I cotransduction
represents predominantly wild-type HBV DNA
We previously reported that when HepG2 cells were cotransduced
with WT HBV recombinant baculovirus at low levels (MOI of 25 pfu/
cell) and rtM204I recombinant baculovirus at high levels (MOI of
100 pfu/cell), an unexpected result was obtained (Heipertz et al.,
2007). At late time points (days 10–25 p.t.), the prediction would be
that the RI levels from the cotransduction should be similar to those
Fig. 7. Increase in the total HBV RI DNA during a WT/rtM204I cotransduction
represents predominately WT HBV DNA. HepG2 cells were transduced on day 0 under
the following conditions: WT HBV MOI=100 pfu/cell, rtM204I MOI=100 pfu/cell,
WTMOI=100 pfu/cell+rtM204IMOI=100 pfu/cell. The cells were harvested at day
10 p.t. (A). A parallel set of cells that were not harvested were subcultured 1:4. The
subcultured set of cells was harvested at day 5 (B) and day 10 (C) post subculture. All
samples were enzymatically digested under the following conditions: Uncut [U], Cla I
cut [C]. Co, cotransduction; P.T., post-transduction; P.S., post subculture; U, Uncut; C,
Cla I cut; RC, relaxed-circular; DS, double-stranded linear. Southern blot hybridization
was carried out using a positive-strand-speciﬁc [α-32P] UTP-radiolabeled riboprobe.
Table 2
Levels of HBV RC and DS DNA in RI at day 10 post cotransduction with WT and M204I
baculoviruses and post subculture of day 10 cotransduced cellsa.
Uncut Cla I cut
HBV DNA (pg) Fold increase
(WT+M204I)
HBV DNA (pg) Fold increase
(WT+M204I)
WT WT+M204I WT WT WT+M204I WT
Day 10 post cotransductionb
RC 113.1 162.4 1.43 102.5 147.4 1.44
DS 105.6 129.5 1.23 98.0 139.1 1.42
RC+DS 218.7 291.9 1.33 200.5 286.5 1.43
Day 5 post subculturec
RC 15.0 30.7 2.05 14.4 34.4 2.39
DS 11.9 21.8 1.83 14.4 17.4 1.21
RC+DS 26.9 52.5 1.95 28.8 51.8 1.80
Day 10 post subculturec
RC 7.9 12.8 1.62 8.0 15.6 1.95
DS 8.1 10.3 1.27 7.6 13.7 1.80
RC+DS 16.0 23.1 1.44 15.6 24.3 1.88
a HepG2 cells were transduced under the following conditions: WT MOI of 100 pfu/
cell, rtM204I MOI of 100 pfu/cell, and WT MOI of 100 pfu/cell+rtM204I MOI of
100 pfu/cell and harvested at day 10 p.t. A parallel set of cultures for each of the three
conditions were subcultured 1:4 and harvested at days 5 and 10 post subculture.
b DNA levels for rtM204I alone were detectable but extremely low (RC:
uncut=2.5 pg, Cla I cut=2.9 pg: DS uncut=3.6 pg, Cla I cut=2.1 pg) and were not
included in the calculations.
c Data for rtM204I alone are not included because the DNA levels were below the
limits of detection.
62 R.A. Heipertz Jr. et al. / Virology 388 (2009) 57–67obtained from WT alone since the RI levels from rtM204I are barely
detectable at that time point. In contrast, at late time points, the RI
levels observed for the cotransduction were approximately two-fold
those observed for WT alone. As shown in Fig. 3, expression of HBV
WT pol alone from the PCFE construct trans-complemented rtM204I
and caused an increase in rtM204I RI DNA levels. The surprising
results obtained from the cotransduction experimental setting led to
the question of whether the observed increased HBV RI levels also
resulted from trans-complementation of rtM204I byWT pol produced
in this case in the context of the intact WT HBV genome. To test this
hypothesis, HepG2 cells were transduced under the following
conditions: WT MOI of 25 pfu/cell, rtM204I MOI of 100 pfu/cell, WT
MOI of 25 pfu/cell+rtM204I MOI of 100 pfu/cell. Cells were
harvested at days 20 and 25 p.t. For each condition, RI DNA was
either uncut [U], digested with EcoR I [E] as a single-cut control, or
digested with Cla I [C] (Fig. 6). The amount of HBV DNA in the RC and
in the DS band from the uncut and Cla I cut lanes were calculated. At
day 20 p.t., a 2.09 fold increase in RC plus DS HBV DNAs was observed
for uncut DNA and a 2.15 fold increase for the RC plus DS HBV DNAs for
Cla I cut DNAwhen comparingWT+rtM204I toWT (Table 1, numbers
indicated in bold). At day 25 p.t., a 1.80 fold increase in RC plus DS HBV
DNAs was observed for uncut DNA and a 1.67 fold increase for the RC
plus DS HBV DNAs for Cla I cut DNAwhen comparingWT+rtM204I to
WT (Table 1, numbers indicated in bold).
To further address the question of whether cotransduction of
HepG2 cells withWTand rtM204I baculoviruses leads to a higher level
of total HBV RI than expected by adding the amount of WT RI to the
amount of rtM204I RI, a different experimental approach was taken,
making use of the baculovirus subculture system (Fig. 7). HepG2 cells
were transduced under the following conditions: WT MOI of 100 pfu/
cell, rtM204I MOI of 100 pfu/cell, WT MOI of 100 pfu/cell+rtM204I
MOI of 100 pfu/cell and harvested at day 10 p.t. A parallel set of
cultures for each of the three conditions were subcultured 1:4 and
harvested at days 5 and 10 post subculture. For each condition, RI
DNA was either uncut [U], digested with EcoR I [E] as a single-cut
control, or digested with Cla I [C] (Fig. 7). The amount of HBV DNA in
the RC and in the DS band from the uncut and Cla I cut lanes werecalculated for all three conditions. For cells transduced with rtM204I
baculovirus alone, a low but detectable level of rtM204I DNA was
measurable at day 10 p. t. (see legend to Table 2), but the rtM204I
DNA levels were below the levels of detection by days 5 and 10 post
subculture. At day 10 p.t., a 1.33 fold increase in RC plus DS HBV DNAs
was observed for uncut DNA and a 1.43 fold increase for the RC plus
DS HBV DNAs for Cla I cut DNAwhen comparing WT+rtM204I toWT
(Table 2, numbers indicated in bold). At day 5 post subculture, a 1.95
fold increase in RC plus DS HBV DNAs was observed for uncut DNA
and a 1.80 fold increase for the RC plus DS HBV DNAs for Cla I cut DNA
(Table 2, numbers indicated in bold) and at day 10 post subculture, a
1.44 fold increase in RC plus DS HBV DNAs was observed for uncut
DNA and a 1.88 fold increase for the RC plus DS HBV DNAs for Cla I cut
DNA when comparing WT+rtM204I to WT (Table 2, numbers
indicated in bold).
In both experimental approaches, cotransduction with WT and
rtM204I baculoviruses yielded higher levels of RC plus DS DNA than
expected with fold increases ranging from 1.33 to 2.15 depending
upon the time point and the experimental design (Tables 1 and 2). In
all conditions, an increase in RC DNA alone and DS DNA alone when
comparing WT+rtM204I to WT was observed. In addition, the fold
increase for the RC band was equal to or greater than the total fold
increase in the RC and DS bands for uncut DNA and this was also true
for the Cla I cut DNA. Similarly the fold increase for the DS band was
equal to or lower than the fold total increase for the RC and DS bands
for uncut DNA and this was also true for the Cla I cut DNA. If the
increase in the HBV RI in the cotransduction setting was caused by
trans-complementation of rtM204I by WT pol, then the expected
result would be that Cla I digestionwould result in a decrease in the RC
band and a concomitant increase in the DS band and this was not the
case. These data clearly indicate that WT HBV DNA that cannot be cut
by Cla I contribute to the observed increased HBV RI levels seen in the
cotransduction setting. We cannot rule out that a small portion of the
increase is caused by trans-complementation of rtM204I by WT pol
because of limits of the experimental approach.
Increase in HBV replication in the presence of a pol-minus HBV construct
Since the observed increase in HBV RI DNA during cotransduction
ofWTand rtM204I is predominantlyWT HBV DNA, the question arose
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issue, we askedwhether the increasewould also be observed if HepG2
cells were cotransduced with WT and a recombinant baculovirus
encoding a pol negative HBV construct instead of a construct
containing a point mutation in pol. An HBV pol negative (pol−)
baculovirus was constructed and designated HBV pol−. The HBV pol−
baculovirus contains an HBV pol sequence similar to the replication-
deﬁcient plasmid pdMfe, utilized in experiments described above. The
HBV pol− baculovirus was created in the same backbone as the WT
HBV baculovirus and utilizes endogenous HBV promoters and
enhancers for expression of all HBV transcripts. Five separate
conditions were utilized: rtM204I MOI of 100+baculovirus MOI of
25 (A), WT MOI of 25+baculovirus MOI of 100 (B), rtM204I MOI of
100+pol−MOI of 25 (C), WT MOI of 25+HBV pol− MOI of 100 (D),
WT MOI of 25+rtM204I MOI of 100 (E). On the indicated days p.t.,
HepG2 cells were harvested for HBV RI DNA (Fig. 8). Cotransduction
with the HBV pol− baculovirus had no effect on the replication of
rtM204I (compare A and C; gray and striped bars in F). However,
contransduction with HBV pol− baculovirus increased the replication
of HBV, as demonstrated in (B) and (D) [also compare black andwhite
bars in F]. The increase in HBV replication in the presence of the HBV
pol− baculovirus is similar to that observed during a WT and rtM204I
cotransduction, as demonstrated in (D) and (E) [also compare white
and textured bars in F]. Collectively, this data indicates thatmutant pol
is not playing a role in the increase in HBV replication observed duringFig. 8. Increase in HBV RI when HepG2 cells are cotransduced with a WT and a pol-minus H
rtM204I HBVMOI=100 pfu/cell+baculovirusMOI=25 pfu/cell (A),WTHBVMOI=25 pfu
MOI=25 pfu/cell (C),WTHBVMOI=25+HBVpol−MOI=100 pfu/cell (D),WTHBVMOI=
at the indicated days p.t. and analyzed by Southern blot. HBV RI DNA bands were visualize
transduction; RC, relaxed-circular; DS, double-stranded linear; SS, single-stranded. Gray bars
MOI=25 pfu/cell+baculovirus MOI=100 pfu/cell; striped bars, rtM204I HBV MOI=10
MOI=100 pfu/cell; textured bars, WT HBV MOI=25 pfu/cell+rtM204I HBV MOI=100 pfa WT and rtM204I cotransduction. In addition, it suggests the
possibility that HBV proteins (HBsAg, HBeAg, HBx, HBcAg) produced
by a HBV virus that does not produce RI (either because it lacks pol or
possesses a replication-deﬁcient pol) can lead to increased levels of
HBV RI in the cotransduction setting.
Discussion
Recombinant baculovirus-mediated HBV transduction of HepG2
cells, which allows highly efﬁcient transduction of WT and mutant
HBV genomes or individual genes and detailed analyses of all post-
entry steps of HBV replication was used to study the effect of the HBV
WT pol expressed alone or in the context of the intact WT HBV
genome on rtM204I replication. We show that HBVWT pol expression
can complement defective mutant rtM204I pol activity resulting in
increased levels of HBV RI DNAs. Analysis of the genetically marked
viral genomes veriﬁed that this restoration resulted from trans-
complementation, rather than recombination. Furthermore, the WT
pol functioned in trans to complement HBV replication regardless of
whether or not the RNA packaging signal, epsilon, which is required to
activate the pol, was provided in cis. In this case, trans-complementa-
tion was achieved by pol over-expression from a packaging-defective
RNA. This ﬁnding indicates that HBV pol can function in trans, without
the requirement of the epsilon RNA in cis, in either RNA packaging or
DNA synthesis. In contrast, we demonstrate that enhanced levels ofBV baculovirus. HepG2 cells were transduced on day 0 under the following conditions:
/cell+baculovirusMOI=100 pfu/cell (B), rtM204I HBVMOI=100 pfu/cell+HBVpol−
25 pfu/cell+rtM204I HBVMOI=100 pfu/cell (E). Cells were harvested for HBVRI DNA
d using a PhosphorImager and quantitated (F) using ImageQuant software. P.T., post-
, rtM204I HBVMOI=100 pfu/cell+baculovirus MOI=25 pfu/cell; black bars, WT HBV
0 pfu/cell+HBV pol−MOI=25 pfu/cell; white bars, WT HBV MOI=25+HBV pol−
u/cell.
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baculoviruses expressing the WT and rtM204I genomes was not due
to trans-complementation of rtM204I by the WT pol. In this case, WT
pol was produced from a full-length, WT pgRNA.
An interesting result generated by this study was that both PCF
(lacking a 3′ epsilon) and PCFE rescued pol-deﬁcient HBV to equal
levels, indicating that the presence of a 3′ epsilon sequence is not
required for functional HBV pol activity. In previous examples of trans-
complementation, a copy of epsilon was provided in ciswithin the pol
construct (Bartenschlager, Junker-Niepmann, and Schaller, 1990;
Chiang et al., 1990; Junker-Niepmann, Bartenschlager, and Schaller,
1990; Okamoto et al., 1993; Radziwill, Tucker, and Schaller, 1990;
Yaginuma et al., 1987); however, a direct comparison with or without
epsilon was not evaluated. Ziermann and Ganem (1996), using a
transfection-based approach, demonstrated that there is no require-
ment for epsilon in cis for the encapsidation function of HBV pol;
however, DNA synthesis activity of the pol was not investigated
(Ziermann and Ganem, 1996). Our data not only agree with Ziermann
et al., but also indicate that the presence of epsilon in ciswithin the pol
construct is not required for reconstitution of viral replication.
Therefore, despite the well-known cis-preference of pol (see below),
there is no strict requirement for epsilon in cis in order for the pol to
function in either RNA packaging or reverse transcription. Our results
indicate that the reported requirement for epsilon to activate the
enzymatic activity of the pol (Lanford et al., 1997; Tavis and Ganem,
1996; Tavis, Massey, and Gong, 1998) previously shown in vitro to be
able to be provided in trans (Pollack and Ganem, 1994; Wang et al.,
1994) can also be provided in trans in vivo in cell culture.
The expression of WT pol in HepG2 cells previously transduced
with either WT or rtM204I HBV recombinant baculovirus resulted in
two separate observations. For WT HBV, expression of WT pol had no
effect on the replication as measured by HBV RI, EC, and CCC DNA
levels. WT HBV has a fully functional pol and replicates to high levels
in the HBV recombinant baculovirus system, so this was not an
unexpected result. These ﬁndings also suggest that levels of HBV
replication in HepG2 cells are not limited by the amount of pol and not
inhibited by addition of excess, functional pol within the limits of the
system used. For rtM204I HBV, the expression of WT pol partially
restored virus replication at the level of RI and EC DNA at late time
points p.t. However, there was no change at the level of CCC DNA for
rtM204I. No change in CCC DNA levels was expected since the levels of
CCC DNA remain elevated even at late time points p.t. when rtM204I
RI and EC DNA are reduced compared to WT (Heipertz et al., 2007).
Using restriction digests, it was demonstrated that this restoration of
rtM204I replication was through trans-complementation of the WT
pol protein functioning to replicate the rtM204I genome. Although
complementation by WT pol did not restore rtM204I replication to
WT replication levels, the restored level was approximately 10-fold
higher than that seen for rtM204I replication in the absence of
complementation.
It is well established that the HBV pol preferentially recognizes the
epsilon of the pgRNA from which it is translated [cis-preference]
(Bartenschlager, Junker-Niepmann, and Schaller, 1990; Hirsch et al.,
1990; Hirsch et al., 1991; Junker-Niepmann, Bartenschlager, and
Schaller, 1990; Knaus and Nassal, 1993; Pollack and Ganem, 1993). In
the study presented here, for rtM204I replication to be occurring at
the levels seen, WT pol has to recognize, in trans, epsilon on the
rtM204I pgRNA. Complementation by WT HBV pol in trans has been
previously demonstrated, by showing that a functional pol protein can
trans-complement a mutant virus that produces no pol (Bartens-
chlager, Junker-Niepmann, and Schaller, 1990; Chiang et al., 1990;
Junker-Niepmann, Bartenschlager, and Schaller, 1990; Okamoto et al.,
1993; Radziwill, Tucker, and Schaller, 1990; Yaginuma et al., 1987) or a
packaging-defective pol (Blum et al., 1991). The current study is
unique in that it addresses the question of the ability of WT HBV pol to
complement the reverse transcriptase activity of a drug-resistant polmutant that arises in chronic HBV patients, yet remains functional in
pgRNA packaging. We conclude from these studies that WT pol, at
least when over-expressed from a RNA deﬁcient in packaging, can
partially restore, through trans-complementation, the replication of
rtM204I at late time points p.t. in the HBV recombinant baculovirus
system.
Given the cis-preference of RNA packaging by the pol, the ability
of WT pol to trans-complement a mutant pol such as rtM204I that is
fully functional in RNA packaging was quite unexpected. We can
suggest at least three possibilities for how WT pol could trans-
complement rtM204I replication. The ﬁrst possibility is that trans-
complementation is due to an increase in the total amount of pgRNA
packaging when PCFE is trans-complementing rtM204I replication.
This would suggest that a single molecule of pol is contained within
nucleocapsids and that the increase in HBV RI DNA observed during
PCFE trans-complementation is due to pol from PCFE recognizing
free (excess) rtM204I pgRNA that is not being encapsidated by the
rtM204I pol. We have tested this possibility and the data clearly
show that there is no increase in packaging when PCFE is trans-
complementing rtM204I replication. The second possibility, based
on current dogma, is that although the total amount of RNA
packaging remains equal, over-expression of WT pol can out-
compete the mutant pol for the mutant pgRNA. This is unlikely
because trans-recognition of pgRNA is much less efﬁcient than cis-
recognition (Bartenschlager, Junker-Niepmann, and Schaller, 1990;
Hirsch et al., 1990; Junker-Niepmann, Bartenschlager, and Schaller,
1990). The third possibility is that more than one pol molecule is
packaged within a capsid such that both the WT and rtM204I
polymerases are co-packaged into the same nucleocapsid. This
would be in contrast to a previous report where it was determined
that duck HBV (DHBV) virions contain only monomers of pol
covalently attached to DHBV DNA (Zhang and Tavis, 2006). However,
our results raise the possibility that more than one pol molecule may
be packaged under speciﬁc circumstances.
We also wanted to determine whether trans-complementation of
rtM204I by WT pol was possibly responsible for the unexpected
enhanced levels of total HBV RI observed at late time points when
HepG2 cells were cotransduced with WT HBV and rtM204I recombi-
nant baculoviruses (Heipertz et al., 2007). Given the fact that WT pol
can trans-complement the rtM204I virus, it was plausible that the
increase in replication observed previously during the cotransduction
might be due to the same event. Our data indicate that increased HBV
RI produced at late time points from the cotransduction are
predominantly WT DNA. We cannot rule out that a low rate of
trans-complementation is occurring during cotransduction that is
below the limits of detection. The failure of the WT pol, which in this
case is translated from a fully functional, packaging-competent
pgRNA, to effectively complement the rtM204I mutant as compared
to the addition of PCFE, is possibly due to the lower levels of pol
expression in the context of the entire WT genome and also the
sequestration of the WT pol by its own pgRNA in cis into
nucleocapsids, due to the cis-preference. Thus, whether the pol, either
WT or variants, expressed in the context of a full-length pgRNA, can
function efﬁciently in trans in a natural infection remains to be
established. In fact, it has been suggested that any contribution from
trans-complementation of aWTandmutant virus in a mixed infection
would be minimal (Litwin et al., 2005). One complication is the fact
that without the selection pressure provided by lamivudine treat-
ment, WT HBV is the more ﬁt virus when compared to rtM204I, and is
therefore preferentially replicated, thus out-competing rtM204I when
both viruses are present within the same hepatocyte. This event has
been observed in patients whose serum HBV DNA levels have
rebounded because of the presence of lamivudine-resistant mutants.
When lamivudine therapy is stopped after the resistant mutants
predominate the population in serum,WT HBV overtakes themutants
after only a few months following cessation, indicating that without
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ance of resistant mutants in patient sera (Cane et al., 1999; Chayama et
al., 1998).
We also show that HBV RI levels are increased similar to those seen
for cotransduction with WT and rtM204I when HepG2 cells were
cotransduced with a WT baculovirus and a pol negative baculovirus
indicating that the rtM204I mutant pol protein or any variant HBV
proteins modiﬁed as a result of overlapping effects of the rtM204I
mutation are not causing the increase. These studies suggest the
possibility that HBV proteins (HBsAg, HBeAg, HBx, HBcAg), expressed
from an HBV virus that does not produce RI (either because it lacks pol
or possesses a replication-deﬁcient pol), present in the cotransduction
setting are either directly or indirectly involved in increasing the
production of RI. This explanation is feasible because HBxAg can boost
HBV replication by trans-activation (reviewed by Bouchard and
Schneider, 2004) and because HBcAg can also function in trans
(Chiang et al., 1990; Junker-Niepmann, Bartenschlager, and Schaller,
1990; Okamoto et al., 1993; Radziwill, Tucker, and Schaller, 1990;
Yaginuma et al., 1987). Addressing the question of which HBV protein
(s) may be functioning to increase RI in the cotransduction setting is
beyond the scope of the current studies.
We conclude from the initial transfection/transduction experi-
ments that a WT pol has the capacity to function to trans-
complement a pol-minus HBV virus without the requirement of
an epsilon in cis for its RNA packaging or enzymatic activity. The pol
also has the capacity to trans-complement the defect in replication
of the rtM204I mutant; however, trans-complementation appears to
require pol over-expression from a packaging-defective RNA. In
contrast, when expressed from an authentic pgRNA, WT pol may
not be able to efﬁciently trans-complement a mutant pol that is not
defective in RNA packaging (such as those arising during current
antiviral therapy). Viral proteins, other than pol may be able to
function in trans more effectively in a mixed infection setting. Given
the high prevalence of drug-resistant HBV variants arising during
current antiviral therapy (Chang et al., 2006; Lai et al., 2003; Lai et
al., 2007; Lee et al., 2006; Mauss and Wedemeyer, 2008), it is
important to understand interactions between the different HBV
variants that may occur within infected hepatocytes, e.g. through
trans-complementation, as show here, in order to develop more
effective antivirals and therapeutic strategies.
Materials and methods
Cell culture
HepG2 cells were maintained at 37 °C in a humidiﬁed incubator at
5% CO2 (Knowles, Howe, and Aden, 1980) in minimal medium (MEM;
Invitrogen) supplemented with 10% heat-inactivated fetal bovine
serum (FBS; HyClone) [MEM-FBS]. Sf21 insect cells were maintained
in Grace's insect medium supplemented with yeastolate (Mediatech,
Inc.), lactalbumin hydrolase (Mediatech, Inc.), and 10% FBS in a
nonhumidiﬁed incubator without CO2 at 28 °C.
Plasmids
The replication-deﬁcientHBVexpressionplasmidpCMV-HBV/POL−,
referred to here as dMfe, is unable to make any pol protein due to a
frame shift mutation, as previously described (Gao and Hu, 2007).
PCFE and PCF WT HBV pol-expressing plasmids were generated as
follows. The WT HBV pol open reading frame, modiﬁed at the
carboxyterminus by the addition of a “Flag-tag” peptide (Asp-Tyr-Lys-
Asp-Asp-Asp-Asp-Lys), was inserted into vector pCl (Promega)
immediately downstream of the CMV promoter element generating
PCF. For PCFE, an additional 341-bp segment encompassing the DR1
and epsilon regions of HBV transcripts was cloned directly down-
stream of the “Flag-tag” of PCF.The entire CMV promoter and modiﬁed HBV pol open reading
frame of PCFE and PCF was isolated by partial Bgl II digestion and
complete Cla I digestion and subsequently cloned into the Bgl II–BstB I
sites of pBlueBac4.5 (Invitrogen), thus generating the transfer vectors
pBBPCFE and pBBPCF, respectively.
Generation of WT HBV pol-expressing baculoviruses
pBBPCFE and pBBPCF were used to generate the recombinant
baculoviruses PCFE and PCF, respectively, according to methods
described previously (Delaney and Isom, 1998).
Generation of HBV pol-baculovirus
The HBV pol− baculovirus was generated from the WT HBV bacu-
lovirus transfer vector pBB4.5HBV1.3 through site-directed mutagen-
esis using the QuickChange II XL Kit (Stratagene). The sequence of the
forward primer used for mutagenesis was: 5′ CAGTTAATGAGAAAA-
GAAGATTGTAATTGATTATGCCTGCCAGGTTT 3′ and the reverse primer:
5′ AAACCTGGCAGGCATAATCAATTACAATCTTCTTTTCTCATTAACTG 3′.
The single base substitution at nt 2626, as highlighted by the bold face,
introduced a stop codon in the pol gene after codon 107. The same
substitution also eliminated the Mfe I restriction site. The mutation
was conﬁrmed by restriction enzyme digestion and transfection check
for HBV replication in the presence or absence (lack of replication) of
the pol-expressing plasmid pBBPCFE. The transfer vector
pBB4.5HBVpol− was used to generate the recombinant baculovirus
HBV pol− according to methods previously described (Delaney and
Isom, 1998).
Transfection and baculovirus transduction
Subconﬂuent HepG2 cells were transfected with 3 μg of plas-
mid pdMfe using Effectene transfection reagent (Qiagen) 20 h
after seeding into 60-mm plates according to the manufacturer's
instructions. Baculovirus transductions were carried out as pre-
viously described (Delaney and Isom, 1998; Heipertz et al., 2007).
Brieﬂy, HepG2 cells were seeded in 60 mm plates at a conﬂuency
of 20–40% 24 h prior to baculovirus transduction. An average
cell count was determined the day of transduction, and used to
calculate the appropriate volume of high-titer baculovirus stock
required to obtain the desired MOI. The baculovirus stock was
diluted in 0.5 mL MEM-FBS, added to HepG2 cells drop-wise, and
allowed to absorb for 1 h at 37 °C with gentle rocking every 15 min.
The baculovirus inoculum was removed by gently washing the cells
two times with PBS, and were re-fed and maintained as described
above.
Restriction enzyme digestion
An appropriate amount of HBV RI DNA was digested with
restriction enzymes EcoR I, Mfe I, or Cla I for the appropriate amount
of time at 37 °C.
HBV DNA extraction and Southern blot analysis
Intracellular HBV RI and nuclear CCC DNA were extracted from
HepG2 cells as previously described in detail (Abdelhamed et al.,
2003; Heipertz et al., 2007; Starkey, Chiari, and Isom, 2009), separated
on 1% agarose gels and Southern blotted. Membranes were hybridized
with a [α-32P] dCTP-radiolabeled probe generated from a full-length,
double-stranded HBV genome or a positive-strand-speciﬁc [α-32P]
UTP-radiolabeled riboprobe, generated by an in vitro transcription
label (Hu et al., 2004; Nguyen and Hu, 2008). Southern blots were
visualized with a PhosphorImager and DNA bands were quantiﬁed
using ImageQuant (Molecular Dynamics).
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Cytoplasmic preparations of HBV nucleocapsids were obtained by
using a modiﬁed protocol that has been previously described (Nguyen
and Hu, 2008). HBV recombinant baculovirus-transduced HepG2 cells
were harvested in a lysis buffer (50 mM Tris–HCl, 1 mM EDTA, 1%
IGEPAL, and protease inhibitor cocktail) followed by centrifugation to
remove the nuclei. The supernatant was treated with DNase I and
RNase for 1 h at 37 °C followed by another centrifugation. Cytoplasmic
nucleocapsids were precipitated by the addition of 35% PEG in 1.75 M
NaCl and incubating at 4 °C for 1 h. Nucleocapsids were then
centrifuged, thoroughly resuspended in TNE (pH=8.0), and stored at
−80 °C. Nucleocapsid preparations were separated on 1% agarose gels
by running overnight and then transferred to nitrocellulose mem-
branes. The following day, membranes were denatured for 10 s and
hybridized with a positive-strand-speciﬁc [α-32P] UTP-radiolabeled
riboprobe, generated by an in vitro transcription label and used for
Southern blot (Hu et al., 2004; Nguyen and Hu, 2008). Southern blots
were visualized with a PhosphorImager and DNA bands were
quantiﬁed using ImageQuant.
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